SelectScience
Join Free
Accelerating Science
NewsLife Sciences

Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk

Quest Diagnostics

34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting

26 May 2016
Weylan Kiam-Laine
Microbiologist

Product news

Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer. Part of the company's newly branded Quest Vantage™ cancer test menu, the tests and accompanying services are designed to provide physicians and patients with clinically actionable data and related support capabilities, including results interpretation, access to genetic counseling and prior authorization for health plan reimbursement.

The new lab-developed tests feature a 34-gene panel that includes several genes not widely found on existing cancer risk panels. Emerging evidence suggests that the presence of certain mutations of these genes may heighten an individual's likelihood of developing certain types of breast, ovarian, endometrial and other cancers.

"The Quest Vantage service combines the latest advances in laboratory diagnostic technology with unmatched convenience and simplicity," said Christopher Fikry, MD, general manager, oncology, Quest Diagnostics. "With this menu, we deliver on our commitment to provide clinically actionable results based on the latest evidence and guidelines. With these insights, physicians and patients are better positioned to manage cancer risk. Clinicians frequently change the frequency and method of screening as a direct result of genetic test results."

Nearly 1.7 million new cancer cases are expected to be diagnosed in 2016, and as many as 10% of those cancers will be the result of an inherited gene mutation. Insight into hereditary risk enables an individual to consider steps, such as more frequent screening, to potentially detect cancer in an earlier, more treatable stage.

Using next-generation sequencing and a proprietary bioinformatics platform, the new Quest Vantage services together aid the detection of genetic variants associated with inherited risk of 15 cancers, including breast, colorectal, pancreatic and renal. They are:

  • MYvantage™ 34-gene Hereditary Comprehensive Cancer Panel, which includes 34 high risk, moderate risk and emerging risk genes associated with a broad spectrum of hereditary cancers.
  • GIvantage™ Hereditary Colorectal Cancer Test, which includes 13 genes predominantly associated with colon and gastric cancers.
  • Qvantage™ Hereditary Women's Health Cancer Test, which includes 14 genes predominantly associated with breast, colon, uterine, and ovarian cancers.

The tests only include genes meeting certain criteria, such as a two-fold increased cancer risk, association with a disease syndrome for which cancer may occur, and guideline support for genetic counseling. GIvantage and Qvantage panels, designed for patients with a limited subset of cancers in their family history, only include genes for which national guidelines provide medical management recommendations for pathogenic or likely pathogenic gene variants. In addition, each gene variant detected during testing is interpreted according to a rigorous process led by the company's medical experts.

Quest intends to share Quest Vantage variant data with ClinVar, an open variant database. The company also shares BRCA variant data with BRCA Share, a user group it co-founded with Inserm, France's Institute of Health, to broaden access to BRCA gene variants.

With the new offerings, the Quest Vantage menu includes approximately a dozen genetic test panels and single-gene test services, including several BRCAvantage® services for assessing risk of breast, ovarian and other cancers based on mutations of the BRCA1, BRCA2 and other genes. The number and composition of the Quest Vantage menu was determined based on counsel from oncologists, obstetricians, gynecologists, medical geneticists and genetic counselors.

The services also incorporate the breadth of Quest's national expertise and scale, which includes 2,300 patient service centers, broad health plan relationships and test ordering connectivity through nearly 600 EHR platforms.

In addition, Quest Vantage is designed to support the patient through the entire testing process, with access to third-party genetic counselors services and support for patients through prior authorization and health plan reimbursement. The company also provides financial assistance to qualified uninsured and underinsured patients. Patients may access test results through the company's myQuest™ patient app.

"These capabilities provide patients and physicians with access to the highest quality testing and robust support capabilities" said Dr. Fikry.

The company will showcase the new Quest Vantage offerings at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7 in Chicago (Quest Exhibit 4089).

Quest Diagnostics is a leader in genetic and cancer diagnostic information services. The company offers up to 700 genetic test services and a broad menu of oncology test services that include blood, biopsy and other specimen types. The company was among the first providers to offer PD-L1 companion and complementary diagnostics for immunotherapies for non-small cell lung cancer and melanoma in the United States.

Links

Quest DiagnosticsCompany website

Tags

Genome AnalysisGenomics, the study of genomes, includes functional genomics, evolutionary genomics and comparative genomics. There are many genomic technologies such as DNA sequencing of whole genomes, computational biology and bioinformatics. DNA and nucleic acids must be isolated and concentrated from cells for analysis with kits, automated analyzers and software. Other useful technologies for studying genomics include PCR, microarrays and electrophoresis.Cellular PathologyCellular Pathology deals with the microscopic analysis of tissue samples and cells. Sample preparation and processing includes fixation, staining, sectioning and slide mounting, using equipment such microtomes and cryostats. In choosing immunohistochemistry and immunocytochemistry kits, consider chromogens, staining method, antibodies, microscopes and imaging.Gene Expression and Molecular CloningMolecular cloning is a set of techniques that utilizes vectors to transfer recombinant DNA into host cells and is an essential tool for investigating the expression of genes and proteins in bacterial or mammalian cells. A variety of vectors optimized for gene cloning and expression in a range of host organisms are available, alongside competent cells for genetic replication. Here, you can explore a range of molecular tools, high-quality genomic and cDNA libraries, premade clones, transformation and transfection reagents and mutagenesis or gene expression detection assays and expression arrays. Find the best gene expression and molecular cloning products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.BiomarkersBiomarkers are biological markers which can be measured and evaluated to indicate a biological state. The use of biomarkers in research and diagnosis can indicate a normal or disease state or drug response of cells / tissues. Biomarkers include genetic markers, cell surface markers such as antigens, antibodies or receptors and secreted molecules such as cytokines. An assay system is required for identification of biomarkers. :Clinical ChemistryBiochemistry (or clinical chemistry) involves the analysis of bodily fluids using chemical tests. Techniques used include HPLC, chromatography, spectroscopy, mass spectrometry, immunochemical, electrophoresis, turbidometric / spectrophotometric assay, MRI and ISE analysis. Tests are often carried out on plasma or serum but urine (urinalysis) and fecal specimens are also processed.Clinical GeneticsMolecular Genetics covers the analysis of hereditary genetic disease and chromosomal abnormalities. Genetics can be analysed using DNA, RNA, and protein microarrays, PCR, RT PCR and DNA sequencing. Genetic equipment includes genetic workstations, thermal cyclers, cooling blocks and electrophoresis products. Diagnostic kits are used for DNA / RNA extraction and purification.Next Generation SequencingNext-generation sequencing (NGS), also known as whole-genome sequencing, high-throughput sequencing and massive parallel sequencing, produces and analyses thousands to millions of nucleotide sequences at once. Sequencing systems operate via varying technologies depending on the manufacturer, including sequencing by synthesis, ligation, pyrosequencing, ion semiconductor and single-molecule real-time sequencing. For NGS, library preparation is paramount to successful sequencing. In this section, explore a range of library preparation kits, from targeted, amplicon-based or hybridization-based kits including epigenomic, transcriptomic and genomic workflows to fragmentation kits. Find the best next-generation sequencing products in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Chem / BioinformaticsCheminformatics and bioinformatics are computational techniques used in chemistry and biology, respectively, for data acquisition, processing and storage. Cheminformatics focuses on compound information, whereas bioinformatics is mainly applied to analysis and modeling of genomics, genetic and sequencing information. Hardware and software is available for data acquisition, analysis, management and storage.Breast CancerBreast cancer is a type of cancer that begins in the cells of the breast and can spread to other parts of the body. Early detection, accurate diagnosis, and targeted treatments are essential for improving patient outcomes. Browse our peer-reviewed product directory to find the best breast cancer research and diagnostic tools, compare products, check reviews, and get pricing directly from manufacturers.Lung CancerLung cancer is a leading cause of cancer-related deaths worldwide, often diagnosed at an advanced stage. Research focuses on early detection, targeted therapies, and personalized treatment strategies. Explore lung cancer research and diagnostic products in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.Colorectal CancerCancer DiagnosticsThere are a wide variety of diagnostic tests for cancer available, and this range continues to expand as our knowledge of cancer improves. Current diagnostic methods include biopsy, imaging and blood tests for known biomarkers. New methods in research development include liquid biopsies and cancer breathalyzers.Clinical NGSNext Generation Sequencing (NGS) refers to the use of massive parallel sequencing of multiple small fragments of DNA. This high-throughput genomic analysis yields enormous amounts of sequence data, which if appropriately analyzed could have huge potential for clinical laboratories. For this to happen there are technique and bioinformatic hurdles to be overcome.MelanomaCancer ResearchAlthough cancer is often referred to as a single condition, it actually consists of more than 100 different diseases. Microscopy, mass spectrometry, high throughput sequencing and flow cytometry are some of the most common techniques employed in cancer research labs.

Related articles